Clinical trials: Resectable Pancreatic Adenocarcinoma
Pancreatic Cancer
Study of Neoadjuvant Treatment in Patients With Pancreatic Cancer That is Potentially Resectable
Phase II study of neoadjuvant treatment with Gemcitabine, Tarceva and Oxaliplatin followed by chemotherapy with Tarceva and Gemcitabine in patients with pancreatic adenocarcinoma with borderline resectability.
- Trial name
- NCT01531712
- Testing
- Gemcitabine, Radiotherapy, Tarceva
- Where
- Spain
- Volunteers
- 6 people
- Sponsor
- Institut Català d'Oncologia
Pancreas Cancer, Adenocarcinoma
Neoadjuvant Treatment of Resectable or Locally Advanced Borderline Pancreatic Adenocarcinoma: Reproducibility of Tumor Measurement in CT VS MRI
Despite important therapeutic advances, pancreatic adenocarcinoma remains one of the cancers with a high mortality rate (4th leading cause of cancer death in the US in 2021), poor prognosis (5-year overall survival rate of 10%)…
- Trial name
- ReMeTTI (NCT05511116)
- Where
- France
- Volunteers
- 48 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix
EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
This clinical trial is studying the amount of EF5 and motexafin lutetium present in tumor cells and/or normal tissues of patients with abdominal (such as ovarian, colon, or stomach cancer) or non-small cell lung cancer.
- Conditions
- Advanced Adult Primary Liver Cancer, Carcinoma of the Appendix, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor
- Trial name
- NCT00087191
- Testing
- EF5, motexafin lutetium, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Pancreatic Adenocarcinoma
Dose-Painted Intensity Modulated Radiotherapy Pancreas (DP-IMRT Pancreas)
This is a prospective non-randomised Phase I/II Radiotherapy (RT) study with patients recruited to escalated dose cohorts. Patients with resectable or borderline resectable (per the National Comprehensive Cancer Network (NCCN)…
- Trial name
- NCT06024824
- Testing
- Dose-Painted Intensity Modulated Radiotherapy
- Where
- 2 sites in Ireland
- Volunteers
- 49 people
- Sponsor
- Cancer Trials Ireland
Resectable Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
A randomized controlled trial, nested within an existing prospective cohort (Dutch Pancreatic Cancer Project; PACAP) and the United Kingdom (UK) Pancreas Cancer: Observations of Practice and survival; PACOPS) according to the…
- Trial name
- RADAR-PANC (NCT04875325)
- Testing
- Standardized surveillance
- Where
- 11 sites in Netherlands, United Kingdom
- Volunteers
- 306 people
- Sponsor
- UMC Utrecht
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer
The PREOPANC-3 study is a randomized, multicenter, phase 3 trial. Patients with resectable pancreatic cancer will be randomly assigned (1:1) to 8 cycles of neoadjuvant mFOLFIRINOX followed by surgery and 4 cycles of adjuvant…
- Conditions
- Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Adenocarcinoma
- Trial name
- PREOPANC-3 (NCT04927780)
- Testing
- Leucovorin Calcium, Fluorouracil, Irinotecan Hydrochloride
- Where
- 21 sites in Netherlands, Sweden
- Volunteers
- 378 people
- Sponsor
- Erasmus Medical Center
Pancreatic Cancer, Pancreatic Adenocarcinoma
Study of Neoadjuvent Chemotherapy Followed by SBRT in Patients With Resectable and Borderline Resectable Pancreatic Cancer
The purpose of this study is to research the effects of delivering full-dose neoadjuvant multi-agent chemotherapy (folfirinox) followed by stereotactic body radiation therapy (SBRT) in patients with resectable pancreatic ductal…
- Trial name
- NCT04130399
- Testing
- Stereotactic Body Radiation Therapy (SBRT), FOLFIRINOX
- Where
- United States
- Sponsor
- Indiana University
Pancreatic Cancer
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
The purpose of this study is to evaluate whether combining cyclophosphamide (CY), pembrolizumab, GVAX and IMC-CS4 is effective and safe in patients with borderline resectable pancreatic cancer.
- Trial name
- NCT03153410
- Testing
- Cyclophosphamide, GVAX Pancreas Vaccine (GVAX), Pembrolizumab
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Pancreatic Ductal Adenocarcinoma
Study of NAC of GA Therapy for Patients With BRPC
Gemcitabine plus nub-paclitaxel (GA) regimen was recently presented at an international oncology meeting and represents a new standard regimen in the treatment of metastatic pancreatic cancer.
- Trial name
- NCT02926183
- Testing
- Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
- Where
- 18 sites in Japan
- Volunteers
- 60 people
- Sponsor
- Wakayama Medical University
Pancreatic Ductal Adenocarcinoma (PDAC)
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
The purpose of this study is to see whether it is possible to give 8 doses of a combination of chemotherapy called FOLFIRINOX before surgery in subjects whose pancreas cancer can be removed with surgery.
- Trial name
- NCT02782182
- Testing
- FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Chicago
Cancer
Ondansetron With/Out Dexamethasone to Prevent Vomiting in Patients Receiving Radiation to the Upper Abdomen
RATIONALE: Antiemetic drugs may help to reduce or prevent vomiting in patients treated with radiation therapy. It is not yet known if ondansetron is more effective with or without dexamethasone in preventing vomiting caused by…
- Trial name
- NCT00016380
- Testing
- dexamethasone, ondansetron, quality-of-life assessment
- Where
- 14 sites in Canada
- Volunteers
- 211 people
- Sponsor
- NCIC Clinical Trials Group
Adenocarcinoma of the Pancreas, Pancreas Cancer
Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B
Standard treatment for newly diagnosed operable pancreatic cancer usually involves undergoing surgery first and then receiving chemotherapy with or without radiation therapy.
- Trial name
- NCT03778879
- Testing
- CCX872-B
- Where
- United States
- Sponsor
- Alan Katz
Pancreatic Neoplasms
Respiratory-gated Stereotactic Body Radiation Therapy for Adenocarcinoma of the Pancreas or Periampullary Region
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary…
- Trial name
- NCT02780648
- Testing
- Stereotactic Body Radiation
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Indiana University
Pancreatic Cancer
Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas
RATIONALE: Drugs used in chemotherapy, such as fluorouracil and gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00079365
- Testing
- fluorouracil, gemcitabine hydrochloride, brachytherapy
- Where
- United States
- Sponsor
- University of South Florida
Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma
Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors
This pilot phase Ib trial studies the side effects and best dose of recombinant EphB4-HSA fusion protein when given together with standard chemotherapy regimens in treating patients with solid tumors that have spread to other…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT02495896
- Testing
- Cisplatin, Docetaxel, Gemcitabine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 61 people
- Sponsor
- University of Southern California
Resectable Pancreatic Cancer
GATA6 Expression as a Predictor of Response to Peri-Operative Chemotherapy in Resectable Pancreatic Adenocarcinoma
To date, there have been no Canadian led neoadjuvant or peri-operative trials, this multicentre design gives the opportunity to build more experience with this strategy across Canada in more institutions.
- Trial name
- NeoPancOne (NCT04472910)
- Testing
- Modified Folforinox (mFFX)
- Where
- 8 sites in Canada
- Volunteers
- 84 people
- Sponsor
- University Health Network, Toronto
PDAC - Pancreatic Ductal Adenocarcinoma, FAP
Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma
This is a prospective, multi-center, single arm, open label, non-randomized study to evaluate the ability of [68Ga]FAPI-46 to detect FAP expressing cells in patients with resectable or borderline resectable PDAC.
- Trial name
- FAPI-46 PDAC (NCT05262855)
- Testing
- [68Ga]FAPI-46
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- SOFIE
Colorectal Adenocarcinoma, Gastric Adenocarcinoma
TAS102 in Combination With NAL-IRI in Advanced GI Cancers
This phase I/II trial studies the best dose and how well trifluridine/tipiracil hydrochloride combination agent TAS-102 (TAS-102) and nanoliposomal irinotecan work in treating patients with gastrointestinal cancers that have…
- Conditions
- Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Non-Resectable Cholangiocarcinoma
- Trial name
- NCT03368963
- Testing
- Nanoliposomal Irinotecan, Trifluridine and Tipiracil Hydrochloride
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Emory University
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma
Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer
This phase III trial compares perioperative chemotherapy (given before and after surgery) versus adjuvant chemotherapy (given after surgery) for the treatment of pancreatic cancer that can be removed by surgery…
- Conditions
- Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Stage I Pancreatic Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8
- Trial name
- NCT04340141
- Testing
- Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium
- Where
- 453 sites in United States, Canada
- Volunteers
- 358 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pancreatic Adenocarcinoma, Pancreatic Cancer Resectable
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
Resectable Pancreatic Cancer represents an important health problem not because of its incidence, but because of its high mortality.
- Trial name
- NCT05181605
- Testing
- Folfirinox and Stereotactic Body Radiotherapy
- Where
- Spain
- Volunteers
- 116 people
- Sponsor
- Instituto de investigación e innovación biomédica de Cádiz